Griffiths J C
Clin Chem. 1980 Mar;26(3):433-6.
The availability of a radioimmunoassay for prostate-specific acid phosphatase has allowed a correlative study between this technique and conventional colorimetric assays in the four clinical stages of prostatic adenocarcinoma. Results of such a study show an increased diagnostic sensitivity of the radioimmunoassay in all stages, but in 14% of Stage IV adenocarcinomas there was no increase in prostatic acid phosphatase above the ranges ordinarily expected for all methods. In cases of benign prostatic hyperplasia, there was an increase associated with in vivo tissue cytolysis, comparable to Stage II and III adenocarcinoma. The sensitivity of the test in Stage I is still low, but testing for combinations of tumor markers might increase the diagnostic yield. Conversely, a different clinical approach might be to establish baseline values in the "at-risk" patient, followed by regular determinations of prostate-specific acid phosphatase activity. Increases in activity within the normal expected range may be interpreted by the clinician as a herald of disease.
前列腺特异性酸性磷酸酶放射免疫测定法的出现，使得在前列腺腺癌的四个临床阶段对该技术与传统比色测定法进行相关性研究成为可能。这样一项研究的结果表明，放射免疫测定法在所有阶段的诊断敏感性均有所提高，但在14%的IV期腺癌中，前列腺酸性磷酸酶并未高于所有方法通常预期的范围。在良性前列腺增生病例中，存在与体内组织细胞溶解相关的升高，这与II期和III期腺癌相当。该检测在I期的敏感性仍然较低，但检测肿瘤标志物组合可能会提高诊断率。相反，一种不同的临床方法可能是在“高危”患者中建立基线值，随后定期测定前列腺特异性酸性磷酸酶活性。临床医生可将正常预期范围内的活性增加解释为疾病的先兆。
